CIK 0000875320
- Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- EIN
- 043039129
- Phone
- +1 617-341-6393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $15,378,206
- in 4 filings, $15.4M under 10b5-1 plans
Net −$15,378,206. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-01 | MCKENZIE DIANA Director | Grant or award | +1,001 | 3,604 | ||
| 2024-05-01 | MCKENZIE DIANA Director | Returned to the company | −1,168 | 2,436 | ||
| 2024-05-01 | MCKENZIE DIANA Director | Grant or award · Deferred Stock Units | +1,168 | 5,990.48 | ||
| 2024-05-01 | Lagarde Michel Director | Grant or award · Stock Option (Right to Buy) | +3,142 | 3,142 | ||
| 2024-05-01 | Kearney Terrence C Director | Grant or award · Stock Option (Right to Buy) | +3,142 | 3,142 | ||
| 2024-05-01 | Garber Alan M Director | Grant or award · Stock Option (Right to Buy) | +3,142 | 3,142 | ||
| 2024-05-01 | CARNEY LLOYD Director | Grant or award | +1,001 | 6,319 | ||
| 2024-05-01 | Bhatia Sangeeta N. Director | Grant or award 10b5-1 | +1,001 | 4,902 | ||
| 2024-04-15 | SACHS BRUCE I Director | Grant or award · Deferred Stock Units | +109.49 | $399.58 | $44K | 14,853.75 |
| 2024-04-02 | Ambrose Kristen SVP & Chief Accounting Officer | Sale 10b5-1 | −240 | $419.00 | $101K | 7,500 |
| 2024-04-01 | Ambrose Kristen SVP & Chief Accounting Officer | Shares withheld for taxes 10b5-1 | −225 | $418.10 | $94K | 7,740 |
| 2024-02-26 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale 10b5-1 | −354 | $425.70 | $151K | 55,804 |
| 2024-02-26 | Sachdev Amit EVP Chief Patient & Ext Af Off | Sale 10b5-1 | −3,004 | $425.70 | $1.3M | 55,325 |
| 2024-02-26 | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Sale 10b5-1 | −883 | $425.70 | $376K | 15,972 |
| 2024-02-26 | Arbuckle Stuart A EVP, COO | Sale 10b5-1 | −5,034 | $425.70 | $2.1M | 49,691 |
| 2024-02-26 | Ambrose Kristen SVP & Chief Accounting Officer | Sale 10b5-1 | −883 | $425.70 | $376K | 7,965 |
| 2024-02-26 | ALTSHULER DAVID EVP, Global Research and CSO | Sale 10b5-1 | −4,239 | $425.70 | $1.8M | 25,813 |
| 2024-02-23 | WAGNER CHARLES F JR EVP & Chief Financial Officer | Shares withheld for taxes | −3,309 | $431.79 | $1.4M | 53,583 |
| 2024-02-23 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Shares withheld for taxes 10b5-1 | −3,309 | $431.79 | $1.4M | 56,158 |
| 2024-02-23 | Sachdev Amit EVP Chief Patient & Ext Af Off | Shares withheld for taxes 10b5-1 | −2,469 | $431.79 | $1.1M | 58,329 |
Page 21 of 27 · 524 trades